🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. Xeloda 150 mg film-coated tablets, ELOXATINE 5 mg/ml, solution à diluer pour perfusion, Folinic acid (as calcium folinate) 10 mg/ml solution for injection/infusion, ELVORINE 100 mg/10 mL, solution injectable, FLUOROURACILE TEVA 1000 mg/20 ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    colon cancer

    phase 2 small molecule active

    1 trial

  2. Xeloda 150 mg film-coated tablets, Folinic acid (as calcium folinate) 10 mg/ml solution for injection/infusion, ELOXATINE 5 mg/ml, solution à diluer pour perfusion, Vectibix 20 mg/ml concentrate for solution for infusion, FLUOROURACILE TEVA 1000 mg/20 ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    metastatic colorectal adenocarcinoma

    phase 2 small molecule active

    1 trial

  3. Xeloda 150 mg film-coated tablets, Xeloda 500 mg film-coated tablets, Paclitaxel 6 mg/mL concentrate for solution for infusion, Herceptin 150 mg powder for concentrate for solution for infusion, GEMZAR 200 mg, poudre pour solution pour perfusion, HALAVEN 0.44 mg/ml solution for injection, Vinorelbine 10 mg/ml concentrate for solution for infusion, GEMZAR 1000 mg, poudre pour solution pour perfusion, evorpacept, HALAVEN 0.44 mg/ml solution for injection

    ALX ONCOLOGY HOLDINGS INC

    Breast Cancer

    phase 2 small molecule active

    1 trial

  4. YERVOY 5 mg/ml concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion, DACARBAZINE

    Immunocore Ireland Limited

    Previously untreated advanced uveal melanoma (UM)

    phase 2 small molecule active

    1 trial

  5. Yigansan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Tourette Disorder

    phase 2 small molecule completed

    1 trial

  6. Yondelis 1 mg powder for concentrate for solution for infusion, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion

    Ningbo Cancer Hospital

    Localized, resected, FIGO stage I (2018 classification), uterine leiomyosarcoma

    phase 2 small molecule active

    1 trial

  7. Yougui granules

    The First People's Hospital of Lianyungang

    Renal Insufficiency, Chronic

    phase 2 small molecule terminated

    1 trial

  8. Z650

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  9. ZEULIDE 3,75 mg, poudre et solvant pour suspension injectable à libération prolongée, Elacestrant

    The George Institute

    Breast cancer

    phase 2 small molecule active

    1 trial

  10. ZG005

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    Biliary Tract Carcinoma

    phase 2 small molecule active

    1 trial

  11. Zanubrutinib, BGB-11417, BGB-11417

    BEONE MEDICINES AUS PTY LTD

    previously untreated WM, Relapsed/Refractory Waldenström’s Macroglobulinemia

    phase 2 small molecule active

    1 trial

  12. Zilovertamab vedotin

    Merck Sharp and Dohme

    Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults

    phase 2 small molecule active

    1 trial

  13. [18F]-olaparib PET; Molecular imaging of DNA damage response by [18F]-olaparib PET

    Disc Medicine

    Head and neck squamous cell carcinoma (HNSCC)

    phase 2 other active

    1 trial

  14. [90Y]Y-PentixaTher, LysaKare 25 g/25 g solution for infusion, [68Ga]Ga-PentixaFor

    Alphapharm Pty Ltd

    Central nervous system (CNS) lymphoma; recurrent or refractory primary or isolated secondary

    phase 2 small molecule active

    1 trial

  15. a standardized physical therapy program

    Hospital Authority, Hong Kong

    Frozen Shoulder

    phase 2 other completed

    1 trial

  16. autologous adipose-derived mesenchymal stem cell transplantation

    Hospital Authority, Hong Kong

    Aging Problems

    phase 2 mab active

    1 trial

  17. autologous anti-BCMA chimeric antigen receptor T cells

    The First People's Hospital of Lianyungang

    ITP

    phase 2 mab active

    1 trial

  18. autologous dendritic cells pulsed with tumor lysate antigen Vaccine

    NORTHWEST BIOTHERAPEUTICS INC

    Giant Cell Glioblastoma

    phase 2 mab terminated

    1 trial

  19. autologous mesenchymal stem cells implantation

    Teva Pharma GmbH

    Tibial Fracture

    phase 2 other completed

    1 trial

  20. autologous skin fibroblasts

    United Therapeutics Europe Ltd

    Wounds and Injuries

    phase 2 mab active

    1 trial

  21. avelumab

    Nektar Therapeutics UK Limited

    Squamous Cell Carcinoma of the Head and Neck (SCCHN)

    phase 2 small molecule terminated

    1 trial

  22. azenosertib

    Zentalis Pharmaceuticals

    High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

    phase 2 small molecule active

    1 trial

  23. bexarotene

    LIGAND PHARMACEUTICALS INC

    Cutaneous T-Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  24. cRGD-ZW800-1

    Disc Medicine

    Squamous cell carcinoma of the larynx and hypopharynx

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources